Four years after he resigned as chief medical officer at Novartis in the wake of a restructuring at the Big Pharma, John Tsai ...

Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service (NHS) ...

As Candel Therapeutics gears up for a planned U.S. approval push for its prostate cancer drug later this year, RTW ...

Johnson & Johnson has paused further enrollment in a phase 2b trial of its AC Immune-partnered Alzheimer’s disease candidate, ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30 patients ...

Sanofi and Teva had already shown in late 2024 that the anti-TL1A antibody, called duvakitug, improved outcomes in ulcerative ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Just as a disciplined a soccer player might pass on a hopeful shot in favor of a better chance later on, the biopharma ...

After an FDA rejection of its spinocerebellar ataxia (SCA) therapy, Biohaven was forced to rethink its strategy—cutting R&D spend by 60% and channeling the spirit of a scrappy startup again as it ...

Danaher Corp. is snapping up patient monitoring medtech Masimo in a $9.9 billion deal aimed at strengthening its diagnostics ...

Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.